UBS Group Issues Positive Forecast for Charles River Laboratories International (NYSE:CRL) Stock Price

Charles River Laboratories International (NYSE:CRL) had its target price upped by UBS Group from $170.00 to $175.00 in a research report report published on Wednesday morning,Benzinga reports. They currently have a neutral rating on the medical research company’s stock.

A number of other analysts have also recently commented on CRL. JPMorgan Chase & Co. boosted their target price on shares of Charles River Laboratories International from $165.00 to $190.00 and gave the company a “neutral” rating in a report on Monday, December 15th. Evercore upped their price objective on shares of Charles River Laboratories International from $250.00 to $260.00 and gave the stock an “outperform” rating in a report on Tuesday, January 13th. Bank of America raised shares of Charles River Laboratories International from a “neutral” rating to a “buy” rating and set a $225.00 target price for the company in a research note on Monday, December 15th. Wall Street Zen cut Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Saturday, February 21st. Finally, Weiss Ratings restated a “sell (d)” rating on shares of Charles River Laboratories International in a research note on Wednesday, January 21st. Ten research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $203.57.

Charles River Laboratories International Price Performance

Shares of NYSE CRL opened at $168.03 on Wednesday. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.29 and a quick ratio of 1.02. Charles River Laboratories International has a 1 year low of $91.86 and a 1 year high of $228.88. The company’s 50-day moving average is $198.54 and its 200 day moving average is $179.76. The stock has a market capitalization of $8.27 billion, a P/E ratio of -56.77, a P/E/G ratio of 2.84 and a beta of 1.63.

Charles River Laboratories International (NYSE:CRL) last announced its earnings results on Wednesday, February 18th. The medical research company reported $2.39 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.33 by $0.06. The firm had revenue of $994.23 million during the quarter, compared to analyst estimates of $986.98 million. Charles River Laboratories International had a positive return on equity of 15.60% and a negative net margin of 3.59%.The business’s revenue was down .8% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.66 EPS. Charles River Laboratories International has set its FY 2026 guidance at 10.700-11.200 EPS. On average, sell-side analysts expect that Charles River Laboratories International will post 9.36 earnings per share for the current year.

Institutional Investors Weigh In On Charles River Laboratories International

Several institutional investors have recently modified their holdings of CRL. Principal Financial Group Inc. raised its stake in Charles River Laboratories International by 84.5% during the 3rd quarter. Principal Financial Group Inc. now owns 104,719 shares of the medical research company’s stock valued at $16,384,000 after buying an additional 47,954 shares during the last quarter. Penserra Capital Management LLC bought a new stake in shares of Charles River Laboratories International in the third quarter worth $533,000. Cooke & Bieler LP increased its position in Charles River Laboratories International by 0.9% during the third quarter. Cooke & Bieler LP now owns 603,877 shares of the medical research company’s stock valued at $94,483,000 after acquiring an additional 5,100 shares during the last quarter. Invesco Ltd. lifted its holdings in Charles River Laboratories International by 11.6% in the second quarter. Invesco Ltd. now owns 1,237,143 shares of the medical research company’s stock valued at $187,712,000 after acquiring an additional 128,785 shares during the period. Finally, Madison Asset Management LLC purchased a new position in Charles River Laboratories International in the third quarter worth about $1,935,000. 98.91% of the stock is owned by hedge funds and other institutional investors.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.